Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 432-441

  Pahl, Jens H W ^a   Ruslan, S Eriaty N ^a   Buddingh, Emilie P ^a   Santos, Susy J ^a   Szuhai, Karoly ^a   Serra, Massimo ^b   Gelderblom, Hans ^a   Hogendoorn, Pancras C W ^a   Egeler, R Maarten ^a   Schilham, Marco W ^a   Lankester, Arjan C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; INTERLEUKIN 5;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL ACTIVATION; CELL SURFACE; CHEMOSENSITIVITY; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TARGET CELL; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OSTEOSARCOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA, EWING; TUMOR CELLS, CULTURED;

EID: 84856015456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2277     Document Type: Article

References (49)

1. Klein MJ, Parisien MV, Scheider-Stock R. Osteogenic tumors. In: Fletcher CMD, Unni and KK, Mertens F editors. World health classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 259-85.
2. van den Berg H, Kroon HM, Slaar A, Hogendoorn PCW. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA". J Pediatr Orthop 2008;28:29-35. (Pubitemid 351628188)
3. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010;15:615-34.
4. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PCW, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer 2011;47: 2431-45.
5. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41. (Pubitemid 39014554)
6. Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011;60:575-86.
7. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16:3901-09.
8. Verhoeven DHJ, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008;45:3917-25.
9. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005;100:7-13. (Pubitemid 41262028)
10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-49.
11. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011;17:2110-19.
12. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-53. (Pubitemid 38339452)
13. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 2008;68:93-106.
14. Szuhai K, Ijszenga M, Tanke HJ, Rosenberg C, Hogendoorn PCW. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genet Cytogenet 2006;166:173-79.
15. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010;49:40-51.
16. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008;68:6661-68.
17. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De GC, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993;13:323-29. 18. Serra M, Reverter-Branch Maurici D, Benini S, Shen JN, Chano T, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004;15:151-60. (Pubitemid 38145532)
18. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 2007;38:1184-91. (Pubitemid 47058157)
19. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302. (Pubitemid 38541581)
20. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104-111. (Pubitemid 350190989)
21. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de BF, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
22. Borner M, Koeberle D, Von MR, Saletti P, Rauch D, Hess V, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008;19:1288-92. (Pubitemid 351911959)
23. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. NEngl J Med 2004;351:337-45. (Pubitemid 38944402)
24. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
25. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
26. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54. (Pubitemid 46211507)
27. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 2010;150:237-42.
28. DoSI, JungWW,KimHS, Park YK. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol 2009;34:797-803.
29. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008;113:1453-61.
30. Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 2007;13:2998-3005. (Pubitemid 46849576)
31. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61. (Pubitemid 46450447)
32. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 2009;15:91-100.
33. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58:1853-64.
34. Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010;19:89-99.
35. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing theGEOhuman colon carcinoma xenograft. Cancer Chemother Pharmacol 2005;56:455-64. (Pubitemid 41549146)
36. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006;12:6517-22. (Pubitemid 44799726)
37. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80. (Pubitemid 46993549)
38. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFRexpressing esophageal squamous cell carcinoma. Int J Cancer 2007;120:781-87. (Pubitemid 46175397)
39. Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, et al. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 2011;130:465-75.
40. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28. (Pubitemid 350075032)
41. Berger C, Krengel U, Stang E, Moreno E, Helene MI. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother 2011;34:550-55.
42. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003.
43. Fan TM. Animal models of osteosarcoma. Expert Rev Anticancer Ther 2010;10:1327-38.
44. Garrido G, Sanchez B, Rodriguez HM, Lorenzano P, Alonso D, Fernandez LE. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. Hybrid Hybridomics 2004;23:168-75. (Pubitemid 38879521)
45. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de BI, de JD, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009;219:294-305.
46. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-29.
47. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010;30:4209-17.
48. Marechal R, De SJ, Nagy N, Demetter P, Lemmers A, Deviere J, et al. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMCCancer 2010;10:340.
49. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S18-S30.